This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

CAMHS won't see you now

GMC to rule on legal cover for GPs

Dyspnoea shows heart risk

Self-reported dyspnoea effectively predicts prognosis in patients undergoing cardiac stress testing, a US study reports.

Researchers studied 17,991 patients who were divided into five groups depending on their symptoms at presentation (none, non-anginal chest pain, atypical angina, typical angina and dyspnoea).

Patients with dyspnoea had four times the risk of sudden death from cardiac causes of asymptomatic patients and more than twice the risk of patients with typical angina.

New England Journal of Medicine 2005; 353:1889-98

C. difficile antimicrobials

Fluoroquinolones are the antimicrobials most associated with episodes of C. difficile-associated diarrhoea, new research shows.

Researchers conducted a retrospective cohort study of 5,619 patients treated over an 18-month period in a single Canadian hospital.

Fluoroquinolones increased risk of C. difficile-associated diarrhoea 3.4-fold. Cephalosporins, macrolides, clindamycin and ?-lactam/?-lactamase inhibitors were intermediate risk antibiotics, increasing risk by 1.6-to 1.9-fold.

Clinical Infectious Diseases 2005;41:1254-60

Genes predict diabetes

Testing for gene variants can predict the risk of developing type 2 diabetes, Swedish researchers show.

Their study examined 2,293 individuals over six years.

Patients with the PPARG PP genotype were at a

70 per cent increased risk of type 2 diabetes and those with the CAPN10 SNP44 TT genotype at a 50 per cent increased risk.

Patients with both genotypes were at a 2.6-fold increased risk of developing the disease.

PLoS Medicine 2005; 2:1-9

Topiramate and migraine

Topiramate successfully treats migraine in children, a US study concludes.

Researchers studied 162 children over an eight-week period, 112 of whom received 2-3mg/kg topiramate daily and the remaining 50 a placebo.

Some 32 per cent of children in the topiramate group had reductions of 75 per cent or more in days they suffered migraine per month compared with just 14 per cent of those treated with placebo.

Headache 2005;45:1304-12

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say